Anumana Announces Collaboration with Novartis for AI-ECG Solutions

See Release

Algorithm Pipeline

Innovative diagnostic tools for detecting rare and hidden disease, based on the world’s largest labeled patient dataset, built to be integrated into existing physician workflows and currently pursuing FDA approval.

Program

Development

Pre-Submission

Validation

Submission

Approval

Low Ejection Fraction

Granted FDA Breakthrough Device Designation

Novartis_logo

Pulmonary Hypertension

Granted FDA Breakthrough Device Designation

janseen_logo

Hyperkalemia

Granted FDA Breakthrough Device Designation

Amyloidosis

Atrial Fibrillation in Normal Sinus Rhythm

Hypertrophic Cardiomyopathy

Myocarditis

Aortic Stenosis

Early Stage Development Programs

Low Ejection Fraction

Granted FDA Breakthrough Device Designation

janseen_logo

Phase: Validation

Pulmonary Hypertension

Granted FDA Breakthrough Device Designation

janseen_logo

Phase: Development

Hyperkalemia

Granted FDA Breakthrough Device Designation

Phase: Development

Amyloidosis

Phase: Development

Atrial Fibrillation in Normal Sinus Rhythm

Phase: Development

Hypertrophic Cardiomyopathy

Phase: Development

Myocarditis

Phase: Development

Aortic Stenosis

Phase: Development

Early Stage Development Programs

Phase: Development

Partner with us!

We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to info@anumana.net